-
Protease Inhibitor Cocktail EDTA-Free: K1010
2026-09-25
K1010 helps limit endogenous protease-mediated degradation during protein extraction and sample preparation, with an EDTA-free formulation intended for workflows sensitive to divalent cations. Use it at the stated dilution for lysate-based assays; do not rely on it where EDTA-dependent metalloprotease inhibition is required, and check compatibility with DMSO-sensitive assays.
-
Bestatin Workflows for Aminopeptidase Research
2026-09-25
Bestatin (Ubenimex) lets researchers probe aminopeptidase activity while also supporting cell-based multidrug resistance studies and chemical-genetic experiments in plants. This practical guide separates reported conditions from suggested workflow choices, with controls to help distinguish target inhibition from broader biological effects.
-
BCA Protein Quantification Kit K4102
2026-09-24
The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit K4102 measures total protein in low-concentration biochemical samples, including many detergent-containing preparations. Use it for research workflows such as sample normalization, not for diagnostic, clinical, or medical testing.
-
Ivermectin: Assay Workflows for Parasitology Research
2026-09-24
Build reproducible parasite motility and viability assays with Ivermectin, a broad-spectrum anti-parasitic agent whose solvent behavior makes stock preparation and vehicle controls central to experimental design. This guide also separates established parasitology applications from a pancreatic cancer study that offers useful assay-design lessons—but no evidence for an ivermectin–GSDMC connection.
-
Pazopanib: From Kinase Blockade to Assay Design
2026-09-23
Pazopanib (GW-786034) inhibits multiple receptor tyrosine kinases, but its effects depend on the biological context being tested. This article connects its vascular signaling profile with ATRX-stratified glioma research and offers a practical framework for interpreting assays without overstating the evidence.
-
ABT-263 (Navitoclax): Reliable Apoptosis Assays
2026-09-23
This scenario-based guide explains how ABT-263 (Navitoclax), SKU A3007, can support mechanistic viability and apoptosis experiments. It covers solvent handling, assay compatibility, mitochondrial biology, orthogonal validation, interpretation, and practical vendor-selection criteria for cancer biology laboratories.
-
L-Ornithine: From Urea Cycle to Liver–Brain Insight
2026-09-22
L-Ornithine is more than a urea-cycle metabolite: it is a practical probe for connecting hepatic nitrogen disposal with astrocyte energy metabolism. This article translates recent OTC–ornithine–ZBTB7A findings into rigorous experimental strategy, product-selection guidance, and a forward-looking translational framework.
-
QPRT and P2Y11 Signaling in Breast Cancer
2026-09-22
Liu and colleagues linked elevated quinolinate phosphoribosyltransferase (QPRT) to breast cancer cell migration and invasion through a signaling axis involving P2Y11, Rho/ROCK, PLC, MLCK, and myosin light-chain phosphorylation. The study’s inhibitor and genetic perturbation strategy provides a useful framework for testing how NAD-related metabolism intersects with purinergic signaling and cytoskeletal remodeling.
-
IPR-803: Reading uPAR Inhibition Correctly
2026-09-21
IPR-803 is a urokinase receptor inhibitor whose biochemical, cellular, and in vivo effects require careful interpretation across assay contexts. This guide connects uPAR–uPA binding, invasion biology, endpoint selection, and translational model design without confusing molecular potency with cellular dosing.
-
MOF Nanoparticles for Non-Invasive Epilepsy Neuromodulation
2026-09-21
The reference study introduces ultrasound-activated piezoelectric MOF nanoparticles designed to cross the blood-brain barrier and selectively modulate epileptic neural circuits. By combining receptor-mediated transport, ultrasound-induced activation, and platinum nanocluster-mediated microenvironment regulation, the platform links non-invasive neuromodulation with targeted control of neuroinflammation and oxidative stress.
-
IL-7, Human Recombinant for Mechanistic Assays
2026-09-20
Explore how IL-7, human recombinant can provide a defined immune-cell context for mechanistic studies, while SARS-CoV-2 PLpro research clarifies how membrane topology, deubiquitination, and proteolysis should shape assay design.
-
Rapamycin in Intestinal Fate and mTOR Assays
2026-09-19
Rapamycin (Sirolimus) is more than a general mTOR inhibitor: it can serve as a causal probe for how polarity, YAP signaling, and mTOR regulate epithelial cell fate. This article translates intestinal stem-cell research into a rigorous framework for assay design, controls, and interpretation.
-
Bone Transport, TGF-β1, and Diabetic Foot Ulcer Healing
2026-09-18
A 2026 rat study identifies TGF-β1/TGFBR1 signaling as a molecular link between bone transport, angiogenesis, and immune regulation during ischemic diabetic foot ulcer repair. The findings support pathway-focused follow-up experiments while showing that TGF-β1 activity may be context-dependent: inhibiting it reduced the healing benefit of bone transport in this model.
-
Ciprofloxacin, Zinc, and RSL3-Induced Ferroptosis
2026-09-18
This study identifies a context-dependent role for ciprofloxacin in ferroptosis: unlike its previously reported protection against erastin-induced ferroptosis, ciprofloxacin enhances RSL3-induced death in cancer cells. The proposed mechanism connects topoisomerase 2β inhibition, mitochondrial DNA stress, STING1–CAV2 signaling, mitochondrial zinc accumulation, and reactive oxygen species production.
-
Kupffer Cell Plasticity in Liver Metastasis
2026-09-17
The reference study shows that liver-metastasis-associated macrophages are maintained not only by recruited monocytes but also by local macrophage proliferation and infiltration of reprogrammed Kupffer cells. Its lineage-tracing, CITE-seq, flow-cytometry, and reporter-mouse strategy provides a framework for interpreting macrophage origin, plasticity, and compensatory niche responses in metastatic liver models.